irinotecan liposomes + cetuximab + vemurafenib

This is an investigational triple-combination therapy being evaluated in the Phase II VICPROIRI trial, sponsored by Fudan University. The regimen consists of irinotecan liposomes (a liposomal formulation of the topoisomerase I inhibitor irinotecan), cetuximab (a monoclonal antibody targeting the epidermal growth factor receptor, EGFR), and vemurafenib (a small molecule inhibitor of the BRAF V600E mutation). This combination is specifically designed for patients with RAS wild-type and BRAF V600E-mutated metastatic colorectal cancer (mCRC) who have progressed after first-line treatment. The rationale for this triple therapy is to overcome resistance to BRAF inhibition, which often occurs in colorectal cancer due to the rapid feedback activation of EGFR signaling. By simultaneously targeting BRAF and EGFR while providing cytotoxic chemotherapy via a liposomal delivery system, the regimen aims to improve efficacy and safety compared to standard irinotecan-based treatments.

Brand names

OnivydeErbituxZelboraf

Other names

irinotecan liposomes + cetuximab + vermofenibVICPROIRI regimenIrinotecan liposomes combined with cetuximab + vemurafenib